A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-Remitting Multiple Sclerosis - Contacts and Locations

A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-Remitting Multiple Sclerosis

This study has been terminated.
Information provided by Bristol-Myers Squibb

Please refer to this study by its ClinicalTrials.gov identifier: NCT00035529

Locations


United States, Connecticut
	Local Institution
	New Haven, Connecticut, United States

United States, Kentucky
	Local Institution
	Louisville, Kentucky, United States

United States, Massachusetts
	Local Institution
	Worcester, Massachusetts, United States

United States, New Jersey
	Local Institution
	Newark, New Jersey, United States

United States, New York
	Local Institution
	New York, New York, United States

United States, North Carolina
	Local Institution
	Charlotte, North Carolina, United States

United States, Pennsylvania
	Local Institution
	Philadelphia, Pennsylvania, United States

United States, Texas
	Local Institution
	Dallas, Texas, United States

United States, Vermont
	Local Institution
	Burlington, Vermont, United States

United States, Wisconsin
	Local Institution
	Madison, Wisconsin, United States

Sponsors and Collaborators

Bristol-Myers Squibb